ARTICLE | Company News
On the heels of a pair of proposed multibillion dollar acquisitions, Sanofi (Euronext:SAN; NYSE:SNY) reported earnings that missed analyst forecasts as the company grapples with a decline in sales for its diabetes and cardiovascular business unit.
The company reported a 4Q17 non-GAAP EPS of €1.06 and sales of €8.69 billion ($10.8 billion) vs. consensus of €1.15 and $8.71 billion ($10.9 billion), respectively. The pharma also guided 2018 EPS growth of 2-5% at constant exchange rates...